Anneke Spoorenberg

Anneke Spoorenberg

Auto-generated profile, based on publicly available information

Anneke Spoorenberg

University Medical Center Groningen, Rheumatology and Clinical Immnuology, Groningen, Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2023 in Rheumatology and Therapy
Verified
Journal Article
Open access
PDF file
YKYvonne M van der Kraan
Yvonne M van der Kraan
DPDavy Paap
Davy Paap
NLNiels Lennips
Niels Lennips
EVElse C A Veenstra
Else C A Veenstra
FWFreke R Wink
Freke R Wink
ASAnneke Spoorenberg
Anneke Spoorenberg
Introduction Within the EULAR recommendations, patient education (PE) is stated as the basis of the management of axial spondyloarthritis (axSpA). However, educational needs are scarcely qualitatively studied in axSpA. Therefore, we aimed to explore experiences and needs of PE in patients with axSpA. Methods A phenomenological approach was used, with semi-structured in-depth interviews with patients with axSpA including broad variation in characteristics. Thematic analysis was applied. To enhance credibility, data saturation, research triangulation, peer debriefing, member checking, theoretical notes, and bracketing were performed. Results Three interrelated themes regarding PE were identified from 20 interviews: illness perception, content, and ‘availability’. Illness perception affects how patients experience and process PE, which consequently influences coping strategies. Prognosis, treatment, and coaching to self-management were identified as the most important content of PE. Regarding ‘availability’, face-to-face PE is preferred for exploring needs, supplemented by self-education, which can be freely applied. Additionally, sufficient time and a comprehensible amount of information were important and participants emphasized the need for axSpA-tailored information for relatives and friends. Participants reported a trusting patient–healthcare provider (HCP) relationship, and multidisciplinary and interdisciplinary attunement between HCPs as prerequisites for effective PE. Conclusions This first qualitative study exploring patients’ experiences and needs of PE in axSpA revealed that prognosis, treatment, and coaching to self-management are important regarding content, and the combination of face-to-face contact and self-education the preferred modalities. It seems essential that patients’ illness perceptions are taken into account for effective PE. These results add relevant insights for future PE guidelines in axSpA.

24 March 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMark Siderius
Mark Siderius
ASAnneke Spoorenberg
Anneke Spoorenberg
FKFrans G M Kroese
Frans G M Kroese
EVEveline van der Veer
Eveline van der Veer
SASuzanne Arends
Suzanne Arends
Background: Bone turnover balance favors bone formation, especially mineralization, during the first 3 years of treatment with TNF-α inhibitors (TNFi). Our aim was to evaluate the course of serum bone turnover markers (BTM) and to investigate if facilitation of mineralization reflected by BTM BALP continues to increase during 6 years of TNFi treatment in patients with ankylosing spondylitis (AS) in daily clinical practice. Methods: Included were outpatients from the University Medical Center Groningen (UMCG) participating in the Groningen Leeuwarden Axial SpA (GLAS) cohort who were treated with TNFi for at least 6 years. Serum markers of collagen resorption, bone regulation, collagen formation and facilitator of bone mineralization (sCTX, OC, PINP and BALP, respectively) were measured at baseline, 3 and 6 months, 1, 2, 4 and 6 years. Z-scores were calculated to correct for age and gender. Results: 53 AS patients were eligible for analyses (66% male, mean age 39±11 years). Disease activity showed rapid and sustained improvement after start of TNFi. Evaluating BTM, sCTX did not significantly change during 6 years of treatment. OC was only significantly increased at 3 months compared to baseline, with median change in Z-score of +0.5. PINP significantly increased at 3 and 6 months and 2 years of treatment, with maximum median change in Z-score of +0.3. Interestingly, BALP was significantly increased at all time points up to and including 2 years of TNFi treatment, with maximum change in median Z-score of +1.2, and decreased thereafter. Conclusion: In AS patients receiving long-term TNFi, bone turnover balance favored collagen formation and facilitation of mineralization during the first 2 years of treatment. Thereafter, at 4 and 6 years of follow-up, BTM Z-scores returned to pre-treatment levels.

7 June 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
RWRick Wilbrink
Rick Wilbrink
ASA. Spoorenberg
A. Spoorenberg
FKF. G. M. Kroese
F. G. M. Kroese
GVG. M. Verstappen
G. M. Verstappen
Background In spite of advancements in treatment of ankylosing spondylitis (AS), its pathogenesis remains incompletely understood. The current evidence suggests that AS is both an autoinflammatory and autoimmune disease involving innate immune cells along with autoreactive lymphocytes. B cells have received little attention regarding their role in the pathogenesis of ankylosing spondylitis (AS), although the available evidence shows presence of B cells at inflammatory sites, imbalances in B cell subsets, presence of autoantibodies (anti-CD74/CLIP), and beneficial effects of B cell depletion (anti-CD20) with rituximab [1]. In AS, the overarching picture portrays increased B cell activation, although it is unclear whether B cells directly affect pathogenesis, or are merely bystanders in the disease process. Objectives Our main objective was to study gene expression and gene signalling pathways involved in B cell activation in AS. To this end, we analysed the transcriptomic profile of isolated peripheral B cells from AS patients, healthy donors (HD) and patients with primary Sjögren syndrome (pSS), a typical B-cell-associated autoimmune disease. Methods RNA was isolated from CD19+ B cells sorted from peripheral blood mononuclear cells of 8 AS patients (mean age 48.0 ± 9.7 years, 63% male, mean ASDAS 2.5 ± 0.7), 8 sex and age-matched HDs (42.3 ± 17.8 years, 63% male) and 8 age-matched pSS patients (48.4 ± 17.8 years, 13% male). Next, characterization of differentially expressed genes was performed using transcriptomic analysis by the NanoString nCounter Autoimmune Profiling Panel, which utilizes a direct hybridization technique without PCR amplification. After normalization and z-score scaling of pathway genes, pathway scores were calculated based on the first principle component using nCounter advanced analysis software. P-values <0.05 were considered significant. Results All samples passed quality control, except for one pSS patient sample that was being flagged as an outlier by the nCounter advanced analyses software. Analysis of differential gene expression between AS patients and HDs revealed upregulation of 8 genes, including MAPK14, KMT2A and PKM, in B cells from AS patients, and downregulation of two genes, DDIT4 and ATG5. In AS patients, the relative expression of B cell receptor (BCR) signalling (n=60 genes) and Fc receptors and phagocytosis (n=55 genes) pathway genes were both significantly enriched compared to HDs (Figure 1). Although not significant, these pathways also displayed higher pathway scores in pSS patients compared to HDs (P=0.30 and P=0.37, respectively). Other gene pathways involved in B cell activation, such as toll-like receptor signalling were not significantly enriched. Conclusion In this study, we observed several differentially expressed genes involved in signal transduction pathways in B cells from AS patients. Furthermore, we showed increased expression of gene pathways involved in B cell activation in patients with AS compared to HDs. The BCR-mediated activation in AS displays similarities to a bona fide autoimmune disease pSS. These results suggest active involvement of B cells in the disease process of AS. Reference [1]Wilbrink, R et al. (2021). B Cell Involvement in the Pathogenesis of Ankylosing Spondylitis. International journal of molecular sciences. Gene pathway scores of (A) B cell receptor signalling and (B) Fc receptors and phagocytosis between AS, pSS patients and HDs. P-values <0.05 were considered significant. Acknowledgements: NIL. Disclosure of Interests Rick Wilbrink: None declared, Anneke Spoorenberg Consultant of: Abbvie, Pfizer, MSD, UCB, Lilly and Novartis, Grant/research support from: Abbvie, Pfizer, Union Chimique Belge (UCB), Novartis, Frans G.M. Kroese Speakers bureau: BMS Roche and Jannsen-Cilag, Consultant of: BMS, Grant/research support from: unrestricted grants from BMS, Gwenny M. Verstappen: None declared.

1 June 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
SKS. Kieskamp
S. Kieskamp
DPD. Paap
D. Paap
MCM. Carbo
M. Carbo
FWF. Wink
F. Wink
RBReinhard Bos
Reinhard Bos
ASA. Spoorenberg
A. Spoorenberg
Background: Up to 40% of ankylosing spondylitis patients report persistently high pain scores of >4 (scale of 0-10) even after responding to long-term TNF-alpha blocking therapy.[1] In other rheumatic diseases, nociplastic pain (due to altered functioning of the nervous system leading to peripheral and central sensitization) is common.[2] In axial spondyloarthritis (axSpA), patient illness and pain perceptions were shown to influence disease outcome.[3] Therefore, we hypothesized that central sensitization and patients’ illness perceptions are associated with persistently high disease activity in axSpA. Objectives: To investigate to what extent central sensitization, pain catastrophizing and patients’ perceptions play a role in axSpA and to explore associations with disease activity. Methods: Between April and September 2019, consecutive outpatients from the Groningen Leeuwarden axSpA (GLAS) cohort,[4] an ongoing large prospective cohort, were included in this study. Besides the standardized assessments, patients filled out three additional questionnaires: Central Sensitization Inventory (CSI), Pain Catastrophizing Scale (PCS) and Revised Illness Perception Questionnaire (IPQ-R). Univariable and multivariable linear regression analyses were used to investigate the association of CSI, PCS and each of the eight subscales of the IPQ-R, and disease activity assessments ASDAS-CRP, BASDAI, and CRP. We corrected for the following potential confounders: gender, symptom duration, BMI, educational level, smoking status and HLA-B27 status. Results: Of 171 included patients, 58% were male, 79% were HLA-B27 positive, median symptom duration was 21 (IQR 10-32), mean ASDAS-CRP 2.1 ± 1.0, mean BASDAI 3.9 ± 2.2 and median CRP 2.9 (IQR 1.2-6.3). Mean CSI score was 37.8 ± 14.1 (scale of 0-100), and 44% of patients scored ≥40 on the CSI.[5] Median PCS score was 15 (IQR 7-22) (scale of 0-52), median IPQ-R illness identity subscore 3 (IQR 2-4) (scale of 0-14) and mean IPQ-R treatment control subscore 18.1 ± 3.4 (scale of 5-25). In univariable regression analysis, CSI and PCS scores and IPQ-R subscores all showed significant associations with ASDAS-CRP, and all except the IPQ-R subscale personal control showed significant associations with BASDAI. Only IPQ-R treatment control was significantly associated with CRP. Central sensitization, two IPQ-R subscales (perceived treatment control and the number of symptoms patients attributed to their axSpA: illness identity) and BMI were independently associated with disease activity assessments BASDAI (R2=0.46) and ASDAS-CRP (R2=0.36) (Figure 1). Conclusion: In this axSpA population with long-term disease, 44% scored above the CSI cutoff point of 40, indicating a high probability of central sensitization. CSI score, illness identity and treatment control were independently associated with disease activity assessments. References: [1]Arends S et al. Clin Exp Rheumatol 2017;35(1):61-8. [2]Meeus M et al. Semin Arthritis Rheum 2012;41(4):556-67. [3]Van Lunteren M et al. Arthritis Care Res (Hoboken) 2018;70(12):1829-39. [4]Arends S et al. Arthritis Res Ther 2011;13(3):R94. [5]Neblett R et al. J Pain 2013;14(5):438-45. Disclosure of Interests: Stan Kieskamp: None declared, Davy Paap: None declared, Marlies Carbo: None declared, Freke Wink Consultant of: Abbvie, Janssen, Reinhard Bos: None declared, Hendrika Bootsma Grant/research support from: Unrestricted grants from Bristol-Myers Squibb and Roche, Consultant of: Consultant for Bristol-Myers Squibb, Roche, Novartis, Medimmune, Union Chimique Belge, Speakers bureau: Speaker for Bristol-Myers Squibb and Novartis., Suzanne Arends Grant/research support from: Grant/research support from Pfizer, Anneke Spoorenberg: None declared

1 June 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
MAM. J. Abdelkadir
M. J. Abdelkadir
MKM. Kuijper
M. Kuijper
CAC. Appels
C. Appels
ASA. Spoorenberg
A. Spoorenberg
JHJ. Hazes
J. Hazes
AWAngelique Weel
Angelique Weel
Background: Early recognition of axial spondyloarthritis (axSpA) patients is difficult for general practitioners within the large amount of chronic low back pain (CLBP) patients1. As a result, several referral strategies have been developed to help physicians identify patients at risk for axSpA. Most referral strategies were developed in secondary care patients with no available data on their impact. The only referral strategy that was developed and validated in primary CLBP patients is the Case Finding Axial Spondyloarthritis (CaFaSpA) strategy, but required an impact analysis before implementation in daily clinical practice2-3. Objectives: The purpose of this study was to assess the impact of using the CaFaSpA referral strategy on patient reported outcome outcomes (PROs) in primary care patients with CLBP at risk for axSpA. Methods: A clustered randomized controlled trial was performed in a primary care setting in the Netherlands. (ClinicalTrials.gov Identifier: NCT01944163). Each cluster contained the general practices from a single primary care practice and their included patients. Clusters were randomized to either the intervention (use of CaFaSpA referral strategy) or the control group (usual care). Primary outcome was disability after 12 months. Secondary outcome was quality of life, pain and fatigue after 12 months. A linear mixed-effects model was used to explore the effects over time according to intention to treat analysis. Results: In total 679 patients were included within 93 GP clusters. Sixty-four percent of our study population were female and mean age was 36 (7.5) years. Overall RMDQ reduced over time both in the intervention and control group (figure 1). The difference in decrease was not statically significant between the groups (p-value 0.81). Estimated mean RMDQ scores over time for the overall intervention and usual care group. EQ-5D increased by 0.03 after 12 months within the intervention group and 0.01 in the control group (not significant) (table 1). The decrease in pain and fatigue did not differ significantly between the intervention and control group. Mean change in PROs after 12 months in the intervention and control group Conclusion: Although the functional disability due to pain reduces over time, there was no positive effect by referring based on the CaFaSPA model. Further data on PROMs for the axSpA patients are under investigation. References: [1]Jois RN et al. Rheumatology (Oxford) 2008;47:1364-1366. [2]van Hoeven L et al. PLoS One 2015; 22;10(7):e0131963. [2]Moons KG et al. Heart 2012;98(9):691-8. Disclosure of Interests: None declared

7 June 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
RWRick Wilbrink
Rick Wilbrink
LWL. Van der Weele
L. Van der Weele
ASA. Spoorenberg
A. Spoorenberg
NVN. De Vries
N. De Vries
FKF. G. M. Kroese
F. G. M. Kroese
GVG. M. Verstappen
G. M. Verstappen
Background The role of B cells in the pathogenesis of ankylosing spondylitis (AS) remains relatively understudied. Nevertheless, available evidence shows presence of B cells at sites of inflammation, higher frequencies of circulating plasmablasts, presence of autoantibodies and beneficial results of B cell depleting therapy with rituximab [1]. We observed previously that a subpopulation of CD27– B cells, characterized by low expression of the complement receptor CD21 (CD21low), is increased in patients with AS and patients with primary Sjogren’s syndrome (pSS), a typical B cell mediated systemic autoimmune disease [2]. These CD21lowCD38lowCD27– B cells display a pro-inflammatory phenotype, suggestive for a pathogenic role. Objectives To gain insight into the origin of these CD21lowCD38lowCD27– B cells we analysed the mutation status of the immunoglobulin heavy chain variable (IGHV) gene regions in the total B cell compartment, CD21low B cell subpopulations and plasmablasts in AS patients in comparison to pSS patients and healthy donors (HD). In addition, we investigated clonal relations between CD21low B cell subpopulations and plasmablasts in AS. Methods RNA was isolated from sorted total B cells (CD19+), two CD21low B cell populations (CD21lowCD38lowCD27– and CD21lowCD38lowCD27+) and plasmablasts (CD19+CD38++CD27+) from peripheral mononuclear cells of 10 AS patients fulfilling the mNY criteria (mean age 46 ± 9 years, 60% male, mean ASDAS 2.3 ± 0.8, all HLA-B27+), 10 sex- and age-matched HDs (mean age 48 ± 21 years, 60% male) and 10 age-matched pSS patients (mean age 46 ± 9 years, 20% male). Repertoire analysis of the B cell receptor heavy chain was performed using high throughput sequencing on the Illumina MiSeq Platform. Sequences were analyzed for degree of somatic hypermutation, usage of immunoglobulin heavy chain variable (IGHV) and joining (IGHJ) regions and clonal relationships. Results IGHV sequences with identical heavy chain CDR3 regions were grouped together and were defined as a clone. Analysis of the IGHV mutation status in CD21low B cells revealed that the majority of clones (71% SD ± 14.1) in the CD21lowCD38lowCD27– subset from patients with AS consisted of clones with a low mutation rate (0-2 mutations in the IGHV region) (Figure 1b). On the contrary, most of the clones in the CD21lowCD38lowCD27+ (49% SD ± 12.5) and plasmablasts (59% SD ± 12.7) subsets were clones with a higher mutation load (>10 mutations in the IGHV region). A similar mutational pattern was seen in pSS patients and HDs. In AS, IGHV3 and IGHJ4 family genes were predominantly used (Figure 1c). However, we observed no differences in family gene usage among B cell subsets nor between groups. To investigate clonal relationships we performed a CDR3 amino acid network analysis on the top 100 most expanded clones per subset in AS patients and found that the CD21lowCD38lowCD27– subset shared more clones with the CD21lowCD38lowCD27+ subset (median 3.0 (0.8-7.0 IQR), p< 0.05) compared to plasmablasts (median 0.0 (0-1.3 IQR). Conclusion This study shows that the expanded circulating CD21lowCD38lowCD27– B cell population in AS consists mainly of antigen-inexperienced cells. The presence of shared clones with their CD27+ counterpart and plasmablasts suggest that the three subsets are to some extent related. Hence, CD21lowCD38lowCD27– B cells may differentiate towards CD21lowCD38lowCD27+ B cells and plasmablasts. The relative roles of these CD21low B cell subsets and plasmablasts in AS pathogenesis remain to be established. References [1]Wilbrink, R et al. (2021). B Cell Involvement in the Pathogenesis of Ankylosing Spondylitis. International journal of molecular sciences. [2]Wilbrink, R et al. (2021). CD27-CD38lowCD21low B-Cells Are Increased in Axial Spondyloarthritis. Frontiers in immunology. Acknowledgements: NIL. Disclosure of Interests Rick Wilbrink: None declared, Linda Van der weele: None declared, Anneke Spoorenberg Consultant of: Abbvie, Pfizer, MSD, UCB, Lilly and Novartis, Grant/research support from: Abbvie, Pfizer, Union Chimique Belge (UCB), Novartis, Niek de Vries: None declared, Frans G.M. Kroese Speakers bureau: BMS Roche and Jannsen-Cilag, Consultant of: BMS, Grant/research support from: BMS, Gwenny M. Verstappen: None declared.